Schön, Michael P.

[["dc.bibliographiccitation.firstpage","2021"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancer Immunology Immunotherapy"],["dc.bibliographiccitation.lastpage","2031"],["dc.bibliographiccitation.volume","61"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Schardt, Anke"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.date.accessioned","2018-11-07T09:03:57Z"],["dc.date.available","2018-11-07T09:03:57Z"],["dc.date.issued","2012"],["dc.description.abstract","Availability of large quantities of functionally effective dendritic cells (DC) represents one of the major challenges for immunotherapeutic trials against infectious or malignant diseases. Low numbers or insufficient T-cell activation of DC may result in premature termination of treatment and unsatisfying immune responses in clinical trials. Based on the notion that cryopreservation of monocytes is superior to cryopreservation of immature or mature DC in terms of resulting DC quantity and immuno-stimulatory capacity, we aimed to establish an optimized protocol for the cryopreservation of highly concentrated peripheral blood mononuclear cells (PBMC) for DC-based immunotherapy. Cryopreserved cell preparations were analyzed regarding quantitative recovery, viability, phenotype, and functional properties. In contrast to standard isopropyl alcohol (IPA) freezing, PBMC cryopreservation in an automated controlled-rate freezer (CRF) with subsequent thawing and differentiation resulted in significantly higher cell yields of immature and mature DC. Immature DC yields and total protein content after using CRF were comparable with results obtained with freshly prepared PBMC and exceeded results of standard IPA freezing by approximately 50 %. While differentiation markers, allogeneic T-cell stimulation, viability, and cytokine profiles were similar to DC from standard freezing procedures, DC generated from CRF-cryopreserved PBMC induced a significantly higher antigen-specific IFN-gamma release from autologous effector T cells. In summary, automated controlled-rate freezing of highly concentrated PBMC represents an improved method for increasing DC yields and autologous T-cell stimulation."],["dc.description.sponsorship","University Medical Center Gottingen for young researchers"],["dc.identifier.doi","10.1007/s00262-012-1262-0"],["dc.identifier.isi","000310888400012"],["dc.identifier.pmid","22527251"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8798"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25006"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-7004"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Controlled-rate freezer cryopreservation of highly concentrated peripheral blood mononuclear cells results in higher cell yields and superior autologous T-cell stimulation for dendritic cell-based immunotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","127"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Dermatology"],["dc.bibliographiccitation.lastpage","130"],["dc.bibliographiccitation.volume","225"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Kretschmer, Lutz"],["dc.contributor.author","Bertsch, Hans-Peter"],["dc.contributor.author","Holzkamp, Ricarda"],["dc.date.accessioned","2018-11-07T09:14:44Z"],["dc.date.available","2018-11-07T09:14:44Z"],["dc.date.issued","2012"],["dc.identifier.doi","10.1159/000342181"],["dc.identifier.isi","000311760700006"],["dc.identifier.pmid","23018645"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9077"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27488"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9832"],["dc.relation.issn","1018-8665"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Squamomelanocytic Tumor of the Nail Unit Metastasizing to a Sentinel Lymph Node: A Dermoscopic and Histologic Investigation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0160096"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Emmert, Steffen"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Zibert, John R."],["dc.contributor.author","Schoen, Margarete"],["dc.contributor.author","Hald, Andreas"],["dc.contributor.author","Hansen, Maria H."],["dc.contributor.author","Litman, Thomas"],["dc.contributor.author","Schoen, Michael Peter"],["dc.date.accessioned","2018-11-07T10:08:37Z"],["dc.date.available","2018-11-07T10:08:37Z"],["dc.date.issued","2016"],["dc.description.abstract","The rapid and strong clinical efficacy of the first-in-class, ingenol mebutate, against actinic keratosis (AK) has resulted in its recent approval. We conducted the first comprehensive analysis of the cellular and molecular mode of action of topical ingenol mebutate 0.05% gel in both AK and uninvolved skin of 26 patients in a phase I, single-center, open-label, within-patient comparison. As early as 1 day after application, ingenol mebutate induced profound epidermal cell death, along with a strong infiltrate of CD4(+) and CD8(+) T-cells, neutrophils, and macrophages. Endothelial ICAM-1 activation became evident after 2 days. The reaction pattern was significantly more pronounced in AK compared with uninvolved skin, suggesting a tumor-preferential mode of action. Extensive molecular analyses and transcriptomic profiling of mRNAs and microRNAs demonstrated alterations in gene clusters functionally associated with epidermal development, inflammation, innate immunity, and response to wounding. Ingenol mebutate reveals a unique mode of action linking directly to anti-tumoral effects."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2016"],["dc.identifier.doi","10.1371/journal.pone.0160096"],["dc.identifier.isi","000383255900002"],["dc.identifier.pmid","27612149"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13695"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39498"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights.access","openAccess"],["dc.title","Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]